Supernus Pharmaceuticals EBIT 2011-2024 | SUPN
Supernus Pharmaceuticals ebit from 2011 to 2024. Ebit can be defined as earnings before interest and taxes.
Supernus Pharmaceuticals Annual EBIT
(Millions of US $) |
| 2023 |
$-5 |
| 2022 |
$46 |
| 2021 |
$86 |
| 2020 |
$174 |
| 2019 |
$149 |
| 2018 |
$144 |
| 2017 |
$100 |
| 2016 |
$54 |
| 2015 |
$21 |
| 2014 |
$-5 |
| 2013 |
$-62 |
| 2012 |
$-42 |
| 2011 |
$-38 |
| 2010 |
$-40 |
Supernus Pharmaceuticals Quarterly EBIT
(Millions of US $) |
| 2024-09-30 |
$41 |
| 2024-06-30 |
$23 |
| 2024-03-31 |
$-3 |
| 2023-12-31 |
$-1 |
| 2023-09-30 |
$8 |
| 2023-06-30 |
$-18 |
| 2023-03-31 |
$5 |
| 2022-12-31 |
$34 |
| 2022-09-30 |
$-2 |
| 2022-06-30 |
$11 |
| 2022-03-31 |
$2 |
| 2021-12-31 |
$6 |
| 2021-09-30 |
$33 |
| 2021-06-30 |
$34 |
| 2021-03-31 |
$13 |
| 2020-12-31 |
$43 |
| 2020-09-30 |
$56 |
| 2020-06-30 |
$46 |
| 2020-03-31 |
$29 |
| 2019-12-31 |
$41 |
| 2019-09-30 |
$40 |
| 2019-06-30 |
$43 |
| 2019-03-31 |
$25 |
| 2018-12-31 |
$40 |
| 2018-09-30 |
$37 |
| 2018-06-30 |
$36 |
| 2018-03-31 |
$31 |
| 2017-12-31 |
$34 |
| 2017-09-30 |
$22 |
| 2017-06-30 |
$26 |
| 2017-03-31 |
$17 |
| 2016-12-31 |
$16 |
| 2016-09-30 |
$20 |
| 2016-06-30 |
$12 |
| 2016-03-31 |
$6 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$5 |
| 2015-06-30 |
$4 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$5 |
| 2014-09-30 |
$-1 |
| 2014-06-30 |
$4 |
| 2014-03-31 |
$-13 |
| 2013-12-31 |
$-11 |
| 2013-09-30 |
$-17 |
| 2013-06-30 |
$-15 |
| 2013-03-31 |
$-18 |
| 2012-12-31 |
$-13 |
| 2012-09-30 |
$-12 |
| 2012-06-30 |
$-9 |
| 2012-03-31 |
$-8 |
| 2011-12-31 |
$-10 |
| 2011-09-30 |
$-10 |
| 2011-06-30 |
$-8 |
| 2011-03-31 |
$-9 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
